Atovaquone and Proguanil

Active ingredient: Atovaquone, Proguanil Hydrochloride

In short: Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of Plasmodium falciparum (P. falciparum) malaria, including in areas where chloroquine resistance has been reported.

Forms & strengthsAtovaquone and Proguanil Hydrochloride Tablets are available containing 250 mg of atovaquone, USP and 100 mg of proguanil hydrochloride, USP. The 250 mg/100 mg tablets are buff, film-coated, round, unscored tablets debossed with A-Pover 2on one side of the …
LabelGolden State Medical Supply, Inc.
Label updatedOct 21, 2026

What is Atovaquone and Proguanil used for?

Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of

Plasmodium falciparum (P. falciparum) malaria, including in areas where chloroquine resistance has been reported.

Atovaquone and proguanil hydrochloride tablets are indicated for the treatment of acute, uncomplicated

P. falciparummalaria. Atovaquone and proguanil hydrochloride tablets have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.

Atovaquone and Proguanil dosage

The daily dose should be taken at the same time each day with food or a milky drink. In the event of vomiting within 1 hour after dosing, a repeat dose should be taken.

Atovaquone and proguanil hydrochloride tablets may be crushed and mixed with condensed milk just prior to administration to patients who may have difficulty swallowing tablets.

Start prophylactic treatment with atovaquone and proguanil hydrochloride tablets 1 or 2 days before entering a malaria-endemic area and continue daily during the stay and for 7 days after return.

One atovaquone and proguanil hydrochloride tablet (adult strength = 250 mg atovaquone/100 mg proguanil hydrochloride) per day.

The dosage for prevention of malaria in pediatric patients is based upon body weight (Table 1).

Weight

(kg) | Atovaquone/

Proguanil HCl

Total Daily Dose | Dosage Regimen

11-20 | 62.5 mg/25 mg | 1 atovaquone and proguanil hydrochloride pediatric tablet daily

21-30 | 125 mg/50 mg | 2 atovaquone and proguanil hydrochloride pediatric tablets as a single daily dose

31-40 | 187.5 mg/75 mg | 3 atovaquone and proguanil hydrochloride pediatric tablets as a single daily dose

> 40 | 250 mg/100 mg | 1 atovaquone and proguanil hydrochloride tablet (adult strength) as a single daily dose

Four atovaquone and proguanil hydrochloride tablets (adult strength; total daily dose 1 g atovaquone/400 mg proguanil hydrochloride) as a single daily dose for 3 consecutive days.

The dosage for treatment of acute malaria in pediatric patients is based upon body weight (Table 2).

Weight (kg) | Atovaquone/

Proguanil HCl

Total Daily Dose | Dosage Regimen

5-8 | 125 mg/50 mg | 2 atovaquone and proguanil hydrochloride pediatric tablets daily for 3 consecutive days

9-10 | 187.5 mg/75 mg | 3 atovaquone and proguanil hydrochloride pediatric tablets daily for 3 consecutive days

11-20 | 250 mg/100 mg | 1 atovaquone and proguanil hydrochloride tablet (adult strength) daily for 3 consecutive days

21-30 | 500 mg/200 mg | 2 atovaquone and proguanil hydrochloride tablets (adult strength) as a single daily dose for 3 consecutive days

31-40 | 750 mg/300 mg | 3 atovaquone and proguanil hydrochloride tablets (adult strength) as a single daily dose for 3 consecutive days

> 40 | 1 g/400 mg | 4 atovaquone and proguanil hydrochloride tablets (adult strength) as a single daily dose for 3 consecutive days

Do not use atovaquone and proguanil hydrochloride tablets for malaria prophylaxis in patients with severe renal impairment (creatinine clearance < 30 mL/min)

. Use with caution for the treatment of malaria in patients with severe renal impairment, only if the benefits of the 3-day treatment regimen outweigh the potential risks associated with increased drug exposure. …

How to take Atovaquone and Proguanil — instructions & advice from the label

Important Administration Instructions

Advise patients to take atovaquone and proguanil hydrochloride tablets at the same time each day with food or a milky drink

.

Advise patients to take a repeat dose of atovaquone and proguanil hydrochloride tablets if vomiting occurs within 1 hour after dosing

.

Advise patients to take a dose as soon as possible if a dose is missed, then return to their normal dosing schedule. However, if a dose is skipped, the patient should not double the next dose.

Severe Cutaneous Adverse Reactions (SCARs)

Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking atovaquone and proguanil hydrochloride tablets immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity

.

Hepatotoxicity

Elevated liver laboratory tests and cases of hepatitis and hepatic failure requiring liver transplantation have been reported with prophylactic use of atovaquone and proguanil hydrochloride tablets

. …

Warnings & precautions

Do not take this medicine if: Atovaquone and proguanil hydrochloride tablets are contraindicated in individuals with known hypersensitivity reactions to atovaquone or proguanil hydrochloride or any component of the formulation

.

Atovaquone and proguanil hydrochloride tablets are contraindicated for prophylaxis of

P. falciparummalaria in patients with severe renal impairment (creatinine clearance < 30 mL/min) because of pancytopenia in patients with severe renal impairment treated with proguanil

.

Absorption of atovaquone may be reduced in patients with diarrhea or vomiting. If atovaquone and proguanil hydrochloride tablets are used in patients who are vomiting, parasitemia should be closely monitored and the use of an antiemetic considered.

Vomiting occurred in up to 19% of pediatric patients given treatment doses of atovaquone and proguanil hydrochloride tablets. In the controlled clinical trials, 15.3% of adults received an antiemetic when they received atovaquone/proguanil and 98.3% of these patients were successfully treated. In patients with severe or persistent diarrhea or vomiting, alternative antimalarial therapy may be required.

In mixed

P. falciparum and Plasmodium vivax (P. vivax)infections, P. vivax parasite relapse occurred commonly when patients were treated with atovaquone and proguanil hydrochloride tablets alone.

In the event of recrudescent

P. falciparuminfections after treatment with atovaquone and proguanil hydrochloride tablets or failure of chemoprophylaxis with atovaquone and proguanil hydrochloride tablets, patients should be treated with a different blood schizonticide.

Elevated liver laboratory tests and cases of hepatitis and hepatic failure requiring liver transplantation have been reported with prophylactic use of atovaquone and proguanil hydrochloride tablets. …

Atovaquone and Proguanil side effects

The following clinically significant adverse reactions are discussed in another section of the labeling:

Vomiting and Diarrhea

.

Hepatotoxicity

.

Severe Cutaneous Adverse Reactions

.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Because atovaquone and proguanil hydrochloride tablets contain atovaquone and proguanil hydrochloride, the type and severity of adverse reactions associated with each of the compounds may be expected. The lower prophylactic doses of atovaquone and proguanil hydrochloride tablets were better tolerated than the higher treatment doses.

In 3 clinical trials (2 of which were placebo-controlled) 381 adults (mean age: 31 years) received atovaquone and proguanil hydrochloride tablets for the prophylaxis of malaria; the majority of adults were black (90%) and 79% were male. In a clinical trial for the prophylaxis of malaria, 125 pediatric patients (mean age: 9 years) received atovaquone and proguanil hydrochloride tablets; all subjects were black and 52% were male. Adverse experiences reported in adults and pediatric patients considered attributable to therapy occurred in similar proportions of subjects receiving atovaquone and proguanil hydrochloride tablets or placebo in all studies. …

Drug interactions

Concomitant administration of rifampin or rifabutin is known to reduce atovaquone concentrations

. The concomitant administration of atovaquone and proguanil hydrochloride tablets and rifampin or rifabutin is not recommended.

Proguanil may potentiate the anticoagulant effect of warfarin and other coumarin-based anticoagulants. The mechanism of this potential drug interaction has not been established. Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with atovaquone and proguanil hydrochloride tablets in patients on continuous treatment with coumarin-based anticoagulants. When these products are administered concomitantly, coagulation tests should be closely monitored.

Concomitant treatment with tetracycline has been associated with a reduction in plasma concentrations of atovaquone

. Parasitemia should be closely monitored in patients receiving tetracycline.

While antiemetics may be indicated for patients receiving atovaquone and proguanil hydrochloride tablets, metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available

. …

About this medicine

Atovaquone and proguanil hydrochloride tablets (adult strength) and atovaquone and proguanil hydrochloride pediatric tablets, for oral administration, contain a fixed-dose combination of the antimalarial agents atovaquone and proguanil hydrochloride.

The chemical name of atovaquone is 2-[

trans-4-(

p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone. Atovaquone, USP is a yellow powder that is practically insoluble in water. It has a molecular weight of 366.84 and the molecular formula C

22H

19ClO

3. The compound has the following structural formula:

The chemical name of proguanil hydrochloride is 1-(4-chlorophenyl)-5-(1-methylethyl)biguanide hydrochloride. Proguanil hydrochloride, USP is a white crystalline powder that is sparingly soluble in water. It has a molecular weight of 290.19 and the molecular formula C

11H

16ClN

5•HCl. The compound has the following structural formula:

Each atovaquone and proguanil hydrochloride tablet (adult strength) contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride (equivalent to 87.4 mg of proguanil). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 152433eb-1341-9cc0-e063-6394a90a1481. Read the full official label on DailyMed.